Innovative vaccine reduces deadly melanoma death rate by 42%

AI summary Summary of article: Moderna and Merck’s optimized mRNA melanoma vaccine reduced the risk of recurrence or death by 42% in a phase 3 trial and shows potential for application approval. pharmaceutical factorymodena(Moderna) and Merck (Merck) a successful messenger…













